ARCHIVES

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

This article is from The Cancer Letter archive.

Vol. 36 No. 6 | June 28, 2013

Download PDF Visit The Full Archive

Related Articles

AHRQ Funds Research To Reduce Medical Errors.

October 19, 2001

Rising Obesity May Result In Higher Cancer Incidence

August 27, 2010

Proflavine Bioassay Ineffective, NCI Says

July 15, 1977

AACR honors Five With Awards Next Month

April 2, 1993

Anticancer Vaccine Trials Due In Three-Four Years; Virus Research Opportunities Described

July 25, 1975

Sledge Elected ASCO President

January 16, 2009